Rationale: Macrophage mannose receptor (MRC) is one of the few molecules known to be involved in lymphocyte trafficking via the lymphatic vessels. In endothelial cells of efferent lymphatics it binds L-selectin on lymphocytes. In afferent lymphatics MRC mediates trafficking of both normal and malignant L-selectin negative cells to the draining lymph nodes.
INTRODUCTION
Leukocyte migration from the periphery into the draining lymph nodes via the afferent lymphatics largely determines the magnitude of immune response within the node. Exit of lymphocytes from the lymph nodes via the lymphoid sinuses into efferent lymphatics also controls the recirculation potential of naïve and activated lymphocytes. Moreover, the lymphatic vasculature also presents an important route for cancer cells to metastasize.
MRC is a scavenger receptor on macrophages and mediates the uptake of mannosylated glycoconjugates. It is also expressed on lymphatics and involved in migration of lymphocytes and melanoma cells into the draining lymph nodes. 1 As a large protein consisting of a cysteine-rich/ricin R-type lectin (CR) domain, a fibronectin type II domain and 8 C-type lectin domains it has the potential to interact with diverse ligands. 2 In vitro binding studies indicate that L-selectin functions as a leukocyte ligand for MRC at least in lymphoid sinuses. 3, 4 Since L-selectin negative cells also migrate in an MRC-dependent manner via the afferent lymphatics, 1 we wanted to identify additional leukocyte counter-receptors for MRC.
Based on the protein structure and function we hypothesized that CD44 might interact with MRC. CD44 is a proteoglycan having at least 40 isoforms due to the alternative splicing and abundant post-translational modifications. It is involved in multitude of functions including apoptosis, adhesion to extracellular matrix and lymphocyte homing from the blood into the lymphoid organs. 5 The standard hematopoietic form of CD44 has glycosaminoglycan side chains, which are predominantly chondroitin-4 and -6-sulfates. In addition, the core protein incorporates sulfate directly to its other oligosaccharide components or amino acids. 6, 7 The best characterized ligand for leukocyte CD44 is hyaluronan present on endothelial cell surface of blood vessels, and this interaction is important in the rolling phase of leukocyte extravasation. In addition, CD44 on mature leukocytes also binds to endothelial selectins, and it can induce signals activating other adhesion molecules (e.g. LFA-1).
5,8

METHODS
Full methods are described in the Supplemental Material.
Animals.
The MRC knockout (MRC-/-) mice were a kind gift from M. Nussenzweig (Rockefeller University). The CD44 knockout (CD44-/-) mice 9 and their wild type (wt) controls were from Jackson laboratories.
Immunohistochemistry.
Frozen sections of mouse peripheral lymph nodes and ears were double stained for MRC and LYVE-1, MRC and F4/80, MRC and CD44, and PV-1 and LYVE-1.
CD44-chimera and MRC constructs.
The chimeric CD44 construct was a kind gift of D. Jackson (University of Oxford) and consisted of a full-length extracellular domain of the standard form of human CD44 fused to human Fc. The MRC constructs generated are presented in Figure 1 .
Co-precipitation and binding studies.
Binding of CD44 and MRC to affinity purified human MRC and CD44 was tested by co-precipitation and detected with immunoblotting. The human material was used with the permission of the Ethical Committee of Turku University Hospital.
CD44-Fc and control chimera with and without chondroitinase treatment were incubated with different MRC transfectants. Bound chimera was detected with FITC-conjugated anti-human IgG and analyzed using flow cytometry.
Binding of CD44 and control Namalwa transfectants to lymphatic endothelial cells in human lymph nodes was tested in ex vivo frozen section assays in the presence of anti-MRC or a control antibody. L-selectin was blocked with a function-blocking antibody Dreg56 during the assays.
Quantitative PCR.
Total RNA was extracted from peripheral lymph nodes, mesenteric lymph nodes, spleen, and liver of wt and MRC-/-mice (n=8). TaqMan Gene Expression Assays (Applied Biosystems) for mouse Sele (E-selectin), FN1 (fibronectin-1), and Spp1 (osteopontin) were used in qPCR and the samples were run as triplicates. The expression values were normalized using mouse β-actin.
In vivo studies.
Fluorescently labeled lymphocytes isolated from lymph nodes and spleens of CD44-/-and wt mice were injected subcutaneously into the footpads of MRC-/-and wt mice. After 12 hours, the popliteal lymph nodes were harvested and cell suspensions were analyzed using flow cytometry.
Statistical analyses.
Data were analyzed using student's t-test (two tailed).
RESULTS
CD44 and MRC interact with each other.
The CR-domain of MRC recognizes chondroitin sulfate A and B and sulfated oligosaccharides of blood group Lewis a and Lewis x as well as sulfated N-glycans of lutropin. 10 Since CD44 has chondroitin sulfate side chains and sulfated carbohydrates linked to its core we tested, whether it could serve as a leukocyte counter-receptor for MRC. We first affinity-purified CD44 from leukocyte lysates and ran lymphatic endothelial cells containing lymph node lysates through the columns. Immunoblotting analyses showed that MRC had specifically interacted with the immobilized CD44. Resiprocal experiments with immobilized natural MRC molecules confirmed the interaction with CD44. The band of CD44 appeared 180kDa suggesting it to be a certain splice variant and/or forms containing glycosaminoglycan side chains of CD44 ( Figure 1A ).
CR domain of MRC binds to chondroitin sulfate side chains of CD44.
To characterize the binding in more detail, we produced recombinant CD44 as an Fc-chimera. It showed a smeary appearance in the gel, typical for CD44 because of its abundant glycosylation. Also a small subpopulation of CD44 molecules were decorated by chondroitin sulfate side chains as demonstrated with three sharp bands showing up after chondroitinase ABC treatment ( Figure 1B ). We then tested the binding of the chimera to transfectants expressing different domains of MRC. The structure of the different domains is depicted in Figure 1C . Flow cytometric analyses showed that CD44 binds to the CR-domain of MRC, but not to the fibronectin type II domain or to the lectin domain ( Figure 1D ). Digestion of the chondroitin sulfate side chains of CD44-Fc with chondroitinase ABC, abolished the binding to MRC ( Figure 1E ). Thus, MRC is a novel ligand for CD44, and the interaction takes place via binding of the glycosaminoglycan side chains of CD44 to the distal CRdomain of MRC.
Expression profiles of CD44 and MRC are compatible with the ligand-receptor pair concept.
MRC is expressed both on LYVE-1 + lymphatic endothelial cells and on a subset of F4/80 + macrophages in the skin of wt mice ( Figure 2A ). In wt mice CD44 is mainly expressed on hematopoietic cells in normal lymph nodes, whereas lymphatic endothelial cells are negative. MRC on the other hand, is present on both afferent and efferent lymphatics and on many macrophages in the sub-capsular sinus of the lymph node ( Figure 2B ). The MRC-/-and CD44-/-mice have apparently normal blood and lymphatic vasculature, as detected by anti-PV-1 and anti-LYVE-1, respectively ( Figure 2C and Online Table I ). Thus, the expression pattern of MRC on lymphatic endothelium and CD44 on lymphocytes is compatible with the possibility that the two molecules interact during lymphocyte migration through lymphatics. Moreover, the expression of previously reported CD44 counter-receptors osteopontin, fibronectin and E-selectin was not altered in MRC-/-mice when compared to wt mice (Online Figure I) , indicating that the absence of one ligand of CD44 (MRC) does not lead to compensatory changes in the expression of other ligands.
CD44-MRC mediates lymphocyte trafficking via the afferent lymphatic vessels in vivo.
The functional relevance of CD44-MRC interaction in supporting lymphocyte trafficking was then studied in adoptive cell transfer experiments. Fluorescently labeled lymphocytes from spleen and lymph nodes of wt and CD44-/-mice were injected into the footpads of wt and MRC-/-recipient mice and their homing to the draining lymph nodes was measured. Wt lymphocyte migration via the afferent lymphatics was impaired in MRC-/-mice confirming our previous findings.
1 CD44 negative lymphocytes also showed diminished capacity to home from the footpad into the draining lymph nodes in wt recipients (on average 54% reduction, P<0.01). Moreover, homing of CD44 negative lymphocytes through MRC-/-lymphatics was reduced to the similar extent (on average 50% reduction, P<0.005). These functional assays show a new role for CD44 in lymphocyte migration via the lymphatics and indicate that MRC-CD44 is a receptor-ligand pair also in vivo ( Figure 3A) . We further tested, whether different lymphocyte populations are selectively dependent on CD44-MRC in their homing to draining lymph nodes. In general, T cells homed significantly better than B cells and more L-selectin -cells homed than expected, when their relative number in the input population was taken into account. However, their relative percentages were comparable in wt and MRC-/-mice (Online Figure II) . Moreover, as L-selectin can easily be shed from the surface of activated lymphocytes during the homing, we directly tested whether CD44-MRC interaction mediates lymphocyte binding to lymphatic endothelium independently of L-selectin using frozen section ex vivo assays. These experiments clearly show that CD44 lymphoma transfectants bind better to lymphatic endothelial cells than their controls in the presence of a function-blocking antibody against L-selectin (P=0.03), and blocking of MRC inhibits this CD44 mediated binding, P=0.03 ( Figure 3B ).
DISCUSSION
In this work we have identified a new ligand-receptor pair mediating lymphocyte trafficking from the periphery into the draining lymph nodes. Although the role of MRC in guiding lymphocyte migration within lymphatics has been known earlier and contribution of CD44 and hyaluronan interaction in leukocyte trafficking in the blood vessels is well recognized, 1,5 CD44-MRC interaction with each other has not been known earlier. Moreover, discovery of CD44 as a lymphocyte surface molecule supporting lymphocyte migration within the lymphatics helps to fill in the so far incomplete understanding of the molecular mechanisms regulating cell trafficking within lymphatics.
Langerhans cell migration into the draining lymph nodes has been reported to be significantly reduced in CD44-/-mice. 11 This is thought to be due to the lack of osteopontindependent chemotaxis, as binding of osteopontin to variant exons of CD44 on Langerhans cells is important in this process. 12, 13 Furthermore, since both CD44 on leukocytes and LYVE-1 on lymphatic endothelium bind hyaluronan, bridging through hyaluronan has been speculated, but not shown, to contribute to leukocyte traffic within the lymphatics.
14 Our current data now for the first time experimentally demonstrate a molecular mechanism by which CD44 mediates lymphocyte traffic in the lymphatic vasculature.
Besides normal leukocytes most malignancies of hematopoietic origin express CD44 and it has also been demonstrated to be an important marker for cancer stem cells. Importantly, high expression of CD44 associates with poor prognosis. [15] [16] [17] Due to multiple pro-tumorigenic functions of CD44, its targeting in hematopoietic malignancies is actively explored in preclinical trials. 16 Based on our findings we speculate that binding of CD44 to MRC is perhaps involved in metastatic spread of malignancies via the lymphatics, thus suggesting that both MRC and CD44 maybe potential drug targets, when metastatic process via the lymphatics needs to be prevented.
In conclusion, leukocyte trafficking within the lymphatics and blood vasculature are equally important for controlling the quality and quantity of the immune response. Based on our results CD44 can be added to those few lymphocyte molecules known to mediate lymphocyte migration within the afferent lymphatics and its potential as a drug target remains to be tested.
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FIGURE LEGENDS Figure 1. CD44 binds to the CR-domain of MRC via its chondroitin sulfate side chains. A, CD44
and MRC proteins were affinity-purified in immobilized forms from human tissue lysates (Precipitation). Thereafter, cell lysates containing CD44 or MRC were run through the column, and the binding of the specific proteins to the immobilized molecules was detected after SDS-PAGE by immunoblotting with the indicated mAbs (Detection). As controls, immunoprecipitations and blottings were performed with a negative control mAb. The arrows point to the specific signals. B, Immunoblotting of recombinant CD44Fc chimera without and with chondroitinase treatment. The bands appearing after chondroitinase treatment are indicated by arrows and presumably reflect the variety of glycosylations typical for CD44. C, The domain structure of the MRC constructs used in the study. D, Binding of CD44Fc-chimera (CD44Ig) to different MRC transfectants. HEK293 cells were transfected with the indicated myc-tagged plasmids, incubated with CD4Ig (neg co) or with CD44Ig (x-axis), permeabilized and then stained for the neg co or c-myc (y-axis) to visualize the transfection efficacy. E, Binding of CD44Fc-chimera without and with chondroitinase pretreatment to MR1 transfectants. 
Novelty and Significance
What Is Known?
 Leukocyte trafficking via the lymphatic vessels is fundamental for proper functioning of the immune system.
 Macrophage mannose receptor (MRC) expressed on the lymphatic endothelial cells can bind to lymphocyte L-selectin to mediate lymphocyte migration into lymphatic vessels.
 CD44 is a multifunctional adhesion molecule that mediates lymphocyte adhesion to extracellular matrix and vascular endothelium.
What New Information Does This Article Contribute?
 Lymphocyte CD44 is a novel counter-receptor for MRC.
 CD44-MRC interaction mediates lymphocyte migration via the afferent lymphatic vessels into the draining lymph nodes under physiological conditions.
Lymphocyte recirculation from the blood to tissues and then via the lymphatic vessels to lymphatic organs and back to blood is crucial for the generation of the immune responses. Here we show that binding of lymphocyte CD44 to MRC, expressed on lymphatic endothelium, is involved in lymphocyte migration from the periphery to the draining lymph nodes. Identification of this novel receptor-ligand pair reinforces the multi-functionality of these two molecules. These findings add to our understanding of the molecular mechanisms guiding lymphocyte entrance into afferent lymphatic vessels and could provide new targets to regulate harmful cell trafficking in inflammatory diseases. 
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CD44 Binds to Macrophage Mannose Receptor on Lymphatic Endothelium and Supports Lymphocyte Migration via Afferent Lymphatics
Salmi: CD44-MRC mediates migration within lymphatics
Supplementary Methods
Animals
The MRC knockout (MRC-/-) mice were a kind gift from M. Nussenzweig (Rockefeller University). The CD44 knockout (CD44-/-) mice (originally made in Hillberg's laboratory 1 ) and their wild type (wt) controls were bought from Jackson laboratories. Age-and sexmatched mice were used in all experiments. The experiments were approved by the ethical committee of Southern Finland.
Immunohistochemistry
Frozen sections of mouse ears were double stained for MRC (FITC-conjugated anti-mouse MRC from BD Pharmingen) and macrophages (PE-TexasRed-conjugated F4/80 from Invitrogen) and MRC and lymphatics (polyclonal anti-LYVE from ReliaTech, followed by Alexa 546 anti-rabbit IgG, Invitrogen). Mouse peripheral lymph nodes were double stained for CD44 (PE-conjugated anti-mouse CD44) and MRC (FITC-conjugated anti-mouse MRC from BD Pharmingen). PV-1 (Meca32, gift from E. Butcher, Stanford University, followed by Alexa488-anti-rat IgG, Invitrogen) and LYVE-1 (polyclonal anti-LYVE from ReliaTech), followed by Alexa 546 anti-rabbit IgG, (Invitrogen) were used to identify vascular and lymphatic endothelial cells, respectively.
CD44-Chimera and MRC Constructs
The chimeric CD44 construct was a kind gift of D. Jackson (University of Oxford) and consisted of a full length extracellular domain of the standard form of human CD44 fused to hinge, CH2 and CH3 of human IgG1Fc in pCDM7Ig vector. It was produced in HEK293 cells and purified by Protein A Sepharose beads. CD4-Ig chimera was used as a control.
The full-length human macrophage mannose receptor cDNA (GeneBank accession number J05550, a kind gift of Dr. M. Taylor, University of Oxford) was first cloned into the expression vector pcDNA3.1 (Invitrogen). It was used as a template to clone distinct protein domains of mannose receptor by amplifying the desired regions by PCR and cloning them into pcDNA3.1. The clones generated encoded the following domains: the cysteine rich/ricin R-type domain (clone MR1; aa 22-142), the fibronectin type II domain (clone MR2+3; aa 161-209), and the C-type lectin domains (MR4; aa 216-1356). In addition, all clones contained the native signal and transmembrane sequences of the human mannose receptor to ensure proper targeting of the expressed proteins (see also Figure 1 ). The clones were further subcloned into pcDNA3.1/myc-His vector (Invitrogen).
Co-Precipitation Studies
Binding of MRC to purified CD44. Human tonsils were lysed in the lysis buffer (150 mM NaCl, 10 mM Tris-base, pH 7.2, 1.5 mM MgCl2, 1% NP-40, 1% Aprotinin and 1 mM PMSF) and the lysates were clarified by centrifugation. Human CD44 was affinity-purified from the lysate using CnBr-activated Sepharose 4B beads coupled to Hermes-3 monoclonal antibody (5mg/ml beads) against human CD44.
2 Meanwhile, human peripheral lymph node was
